Recently, Metro Health – University of Michigan Health, an affiliate of University of Michigan Health, announced that it reduced incidence of hypoglycemia by more than 54% and experienced a 40% decline in hyperglycemia since implementing personalized insulin dosing software. Glytec is marketing the software as the eGlycemic Management System® (eGMS).
Extensive research links poor glycemic control to higher rates of complications – regardless of a preexisting diabetes diagnosis. To address these challenges, Metro Health implemented Glytec’s eGMS at its 208-bed hospital in Wyoming, Mich., in August 2020 and expanded its use to include both the intravenous and subcutaneous offerings in September. In addition to fewer instances of both hyperglycemia and hypoglycemia, Metro Health accelerated its time to target blood glucose for hyperglycemic patients by 30%, reduced insulin-related medication errors, and optimized clinician, nursing, and pharmacy workflows.
Metro Health is the first healthcare facility to benefit from a fully remote installation of Glytec’s eGMS software. Within a month of implementing Glytec, Western Michigan endured its most significant surge of COVID-19 hospitalizations and Metro Health was pushed to its capacity. As a result of COVID-19 order sets calling for the use of corticosteroids, incidents of hyperglycemia rose and over half of Metro Health’s patients were using Glytec’s eGMS to stabilize their blood glucose levels more quickly.
“Poor glycemic control can lead to increased length of stay, higher readmissions, and overall worse outcomes,” says Jacob Stremers, DO, attending hospitalist at Metro Health. “Which is why improving upon the manual, industry-standard approach was an important initiative for Metro Health. Glytec’s eGMS software has been a key component to advancing our glycemic management practices while strengthening patient safety and supporting our clinicians.”
– This article originally appeared on Endocrine News.